|Day Low/High||26.51 / 27.35|
|52 Wk Low/High||14.81 / 42.17|
Both pharma companies are promising names that easily could become buyout targets.
Portola Pharmaceuticals, Esperion Therapeutics and Medicines were among the biotech stock movers in premarket trading on Friday.
Investors in Portola Pharmaceuticals, Inc. saw new options become available this week, for the September 15th expiration.
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.
The most recent short interest data has been released for the 11/30/2016 settlement date, which shows a 693,347 share increase in total short interest for Portola Pharmaceuticals, Inc. , to 5,883,540, an increase of 13.36% since 11/15/2016.
Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2017 expiration.
Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.
Conference Call Today at 4:30 p.m. ET
Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the June 2017 expiration.
If Approved, Betrixaban, an FDA Fast Track-Designated Therapy, Would Be First Anticoagulant for Hospital to Home Prevention of VTE in this High-Risk Patient Population
Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.
Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the November 18th expiration.
In highlights from this week's trading diary and posts, Kass tells us about underlying risks in speculative biotechs and how Donald Trump's voice makes bonds slide.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.